Video

Dr. Seymour on the Kinase Selectivity of BTK Inhibitors in CLL

Erlene Seymour, MD, discusses the kinase selectivity of BTK inhibitors in chronic lymphocytic leukemia.

Erlene Seymour, MD, an assistant professor at Wayne State University School of Medicine and a hematologist/oncologist at Barbara Ann Karmanos Cancer Institute, discusses the kinase selectivity of BTK inhibitors in chronic lymphocytic leukemia (CLL).

There is a highly specific kinase receptor binding in newer BTK inhibitors, says Seymour. For example, acalabrutinib (Calquence) and zanubrutinib (Brukinsa) have less binding on EGFR, therefore, it is believed that these agents will cause less gastrointestinal adverse effects in patients with CLL. Additionally, there is not as much binding on targets that are important for platelet inhibition with these BTK inhibitors, which could result in less bleeding in this patient population, adds Seymour.

The BTK inhibitors that are currently under development are being designed to have more favorable toxicity profiles, concludes Seymour.

Related Videos
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Marc-Oliver Grimm, MD
Chun Chao, PhD, MS
Mikkael A. Sekeres, MD
Noa Biran, MD
Ranee Mehra, MD, professor, medicine, medical oncology; director, Head and Neck Medical Oncology, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical System
Sumanta Kumar Pal, MD, FASCO, chair, Kidney and Bladder Cancer Disease Team; co-director, Kidney Cancer Program; professor, vice chair, Academic Affairs, Department of Medical Oncology & Therapeutics Research, City of Hope
Alfred L. Garfall, MD, MS
David Braun, MD, PhD